Adverse Events and Tolerability of Combined Durvalumab and Tremelimumab versus Durvalumab Alone in Solid Cancers: A Systematic Review and Meta-Analysis

Background: Recently, the combination of durvalumab and tremelimumab, two immune checkpoint inhibitors, for the treatment of different types of cancers has been considered; however, its overall effects, including its safety, are still unclear and need to be further investigated. Objectives: The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Fahmy, Omar, Ahmed, Osama A. A., Khairul-Asri, Mohd Ghani, Alhakamy, Nabil A., Alharbi, Waleed S., Fahmy, Usama A., El-Moselhy, Mohamed A., Fresta, Claudia G., Caruso, Giuseppe, Caraci, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138649/
https://www.ncbi.nlm.nih.gov/pubmed/35625837
http://dx.doi.org/10.3390/biomedicines10051101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138649/
https://www.ncbi.nlm.nih.gov/pubmed/35625837
http://dx.doi.org/10.3390/biomedicines10051101

Ejemplares similares